Navigation Links
Mylan Added to NASDAQ-100 Index
Date:12/14/2009

PITTSBURGH, Dec. 14 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that the company will be added to the NASDAQ-100 Index Dec. 21. Mylan's common shares will also be included in NASDAQ's PowerShares QQQ.

Mylan Chairman and CEO Robert J. Coury said: "We are extremely pleased to join NASDAQ's most widely followed index of leading companies. This development marks yet another significant milestone for Mylan and reflects the rapid growth and strong potential of our highly integrated and diversified global pharmaceuticals platform. Furthermore, this event underscores our reputation and performance as one of the world's most dynamic, high quality and growth-oriented companies."

The NASDAQ-100 Index consists of 100 of the largest, most innovative domestic and international non-financial securities listed on The NASDAQ Stock Market based on market capitalization. The Index reflects companies across major industry groups, including computer hardware and software, telecommunications, retail and wholesale trade, and biotechnology.

PowerShares QQQ is an Exchange Traded Fund (ETF) that seeks to replicate the NASDAQ-100 Index. It is used by investment professionals, private investors and financial advisors.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Mylan Receives Approval for Generic Version of Antiepileptic Keppra(R) 1000 mg
2. Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
3. Mylans President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
4. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
5. Mylan Schedules Third Quarter 2009 Financial Results Conference Call and Live Webcast
6. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
7. Capecitabine Added to Standard Treatment Given Before Surgery Helps to Eradicate Tumours in Patients With Early Breast Cancer
8. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
9. Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimers Disease
10. Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated
11. Karmanos Researchers Find Non-Toxic Agents Added to Conventional Chemotherapy Decrease Survival of Colon Cancer Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  Tandem Diabetes Care®, ... company and manufacturer of the t:slim® and t:flex™ ... into non-exclusive Development Agreements with Dexcom, Inc. to ... pumps with the Dexcom G5 and G6 continuous ... next generation pump platform with Dexcom,s future CGM ...
(Date:7/30/2015)...  Amgen (NASDAQ: AMGN ) today announced ... Key results include: , Total revenues increased ... to $5,370 million, with 6 percent product sales ... Prolia ® (denosumab), Sensipar ® (cinacalcet), ... (denosumab). Unfavorable changes in foreign exchange rates impacted ...
(Date:7/30/2015)... 30, 2015 Eisai Inc. announced today that ... United States , European Union and ... respectively) for eribulin, for the treatment of patients with ... chemotherapy for advanced or metastatic disease. ... pivotal global Phase 3 clinical trial (Study 309), which ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... July 27, 2011 Reportlinker.com announces that ... in its catalogue: India ... Till 2016 http://www.reportlinker.com/p0575381/India-Cardiac-Catheters-and-Guidewires---Market-Trends-Till-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Surgical_Equipment ... This market report provides vital ...
... 26, 2011 Symmetry Medical Inc. (NYSE: SMA ... orthopaedic device industry and other medical markets, announced today that ... period ending July 2, 2011 before the market opens on ... conference call at 8:00 a.m. ET on Thursday, August 4, ...
Cached Medicine Technology:India Cardiac Catheters and Guidewires - Market Trends Till 2016 2India Cardiac Catheters and Guidewires - Market Trends Till 2016 3Symmetry Medical to Report Second Quarter 2011 Financial Results on August 4, 2011 2
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... of All Types " from NBC talked about a woman’s unfortunate experience having ... performed sclerotherapy on her face, which resulted in blistering, swelling, bruising, and pain. ...
(Date:7/31/2015)... ... July 31, 2015 , ... In the most recent testosterone lawsuit ... the Northern District of Illinois, Androgel testosterone attorneys report that a “Mini Status Conference” ... was made recording the minutes of the status conference, which was held that day, ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... India ... United States for temporary work, study or family visit for the past 25 years. ... 80s and 90s are able to travel and spend time with their children and ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... launched a Balloon Sinuplasty website to inform potential Nashville area sinus sufferers ... that can be used to determine if someone is a good candidate for ...
(Date:7/30/2015)... ... July 30, 2015 , ... Dale Sky Jones, Executive Chancellor of Oaksterdam ... International Cannabis Professionals Expo held at the Caribe Royal All Suites Hotel and Convention ... Expo is the largest medical cannabis expo in the country and this year’s ...
Breaking Medicine News(10 mins):Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 2Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 4Health News:India Network Visitor Health Insurance Announces Completion of Food Grains Distribution to Godavari Pushkaram Visitors, Andhra Pradesh, India 2Health News:India Network Visitor Health Insurance Announces Completion of Food Grains Distribution to Godavari Pushkaram Visitors, Andhra Pradesh, India 3Health News:Nashville Otolaryngologist Dr. David Gilpin Launches Balloon Sinuplasty Website 2Health News:Nashville Otolaryngologist Dr. David Gilpin Launches Balloon Sinuplasty Website 3Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 2Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 3Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 4Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 5
... in oleic acid may prevent development of ulcerative colitis , ... olive oil may help protect against ulcerative colitis, a new ... that causes ulcers in the lining of the rectum and ... study found that people whose diet was rich in oleic ...
... in the voluntary recall include Tylenol, Tylenol Plus, Motrin ... McNeil Consumer Healthcare on Friday recalled more than 40 ... because some of the medications may not meet federal ... recall include Tylenol, Tylenol Plus, Motrin, Zyrtec and Benadryl. ...
... in breast milk of fatty acid that promotes brain ... -- Very premature infants have higher levels of DHA ... growth and development of the brain -- when their ... , Researchers say a deficiency in DHA (docosahexaenoic acid) ...
... programs needed to address vision loss, experts say , SATURDAY, ... of visual impairment, blindness, diabetic eye disease and cataracts than ... analysis included data from more than 4,600 participants in the ... participants were of Mexican descent and aged 40 and older. ...
... ... Hearing Aids on May 18th during Hearing Aid Roundup , ... New Braunfels, TX (Vocus) April 30, 2010 -- Estes Audiology and ... aids and mosey on down to the Hearing Aid Roundup at Estes Audiology in New Braunfels ...
... ... to announce the launch of her brand-new blog, TheCancerHelpBlog.com. Here, those on a cancer journey ... of lymphedema on the human body, the first topic of a series. Visit her web ... ...
Cached Medicine News:Health News:Olive Oil May Protect Against Bowel Disease 2Health News:DHA Supplements for Mom Good for Preemies 2Health News:Eye Disease Rates High Among Latino Americans 2Health News:Estes Audiology and SERTOMA Club Windcrest Celebrate Better Hearing and Speech Month with Hearing Aid Roundup 2Health News:Estes Audiology and SERTOMA Club Windcrest Celebrate Better Hearing and Speech Month with Hearing Aid Roundup 3Health News:The Cancer Help Store Debuts New Blog with Information About Lymphedema and Cancer 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: